These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25786315)

  • 1. [Catecholaminergic neurons of mammalian brain and neuromelanin].
    Sukhorukova EG; Alekseeva OS; Korzhevskii DE
    Zh Evol Biokhim Fiziol; 2014; 50(5):336-42. PubMed ID: 25786315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the origin and significance of neuromelanin.
    Graham DG
    Arch Pathol Lab Med; 1979 Jul; 103(7):359-62. PubMed ID: 582279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative biology of neuromelanin and lipofuscin in the human brain.
    Double KL; Dedov VN; Fedorow H; Kettle E; Halliday GM; Garner B; Brunk UT
    Cell Mol Life Sci; 2008 Jun; 65(11):1669-82. PubMed ID: 18278576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease.
    Saper CB; Sorrentino DM; German DC; de Lacalle S
    Ann Neurol; 1991 Jun; 29(6):577-84. PubMed ID: 1892359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional effects of neuromelanin and synthetic melanin in model systems.
    Double KL
    J Neural Transm (Vienna); 2006 Jun; 113(6):751-6. PubMed ID: 16755379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra.
    Usunoff KG; Itzev DE; Ovtscharoff WA; Marani E
    Arch Physiol Biochem; 2002 Oct; 110(4):257-369. PubMed ID: 12516659
    [No Abstract]   [Full Text] [Related]  

  • 10. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update.
    d'Ischia M; Prota G
    Pigment Cell Res; 1997 Dec; 10(6):370-6. PubMed ID: 9428003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin of the human substantia nigra: an update.
    Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
    Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Sepia melanin as a PD model to describe the binding characteristics of neuromelanin - A critical review.
    Schroeder RL; Double KL; Gerber JP
    J Chem Neuroanat; 2015; 64-65():20-32. PubMed ID: 25681296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
    Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
    Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
    Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholaminergic neurons in the parabrachial nucleus of normal individuals and patients with idiopathic Parkinson's disease.
    Goto S; Hirano A
    Ann Neurol; 1991 Aug; 30(2):192-6. PubMed ID: 1680303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuromelanin in neurons of substantia nigra lacking tyrosine hydroxylase].
    Grigor'ev IP; Sukhorukova EG; Kolos EA; Korzhevskiĭ DE
    Morfologiia; 2012; 141(2):65-7. PubMed ID: 22913142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.